SEC Tracker
Get the app

LENZ Therapeutics LENZ

LENZ Therapeutics Q1 FY26: revenue $1.9M; diluted EPS −$1.32

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers LENZ Therapeutics reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$1.9MAgainst $0 in Q1 FY2510-Q income statement, on EDGAR
  2. Net income−$41.5MAgainst −$14.6M in Q1 FY2510-Q income statement, on EDGAR
  3. Diluted EPS−$1.32Against −$0.53 in Q1 FY2510-Q income statement, on EDGAR
  4. Cash and cash equivalents$24.8M+8% from $23.0M in Q1 FY2510-Q balance sheet, on EDGAR
  5. Cash from operations−$33.6MAgainst −$16.0M in Q1 FY2510-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when LENZ Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float $300M to $2B, nearest public float first, as each company reports it on its annual report cover.

  1. ImmunityBio IBRX public float $690M, Jun 30, 2025
  2. Vir Biotechnology VIR public float $689M, Jun 30, 2025
  3. Anavex Life Sciences AVXL public float $708M, Mar 31, 2025, over 18 months old
  4. Relay Therapeutics RLAY public float $586M, Jun 30, 2025
  5. Ginkgo Bioworks Holdings DNA public float $553M, Jun 28, 2025